Innovia Medical Expands Single-Use Instrument Product Line into the US with Gynecology Product Cervical Rotating Biopsy Punch

Innovia Medical (“Innovia”) is thrilled to announce the expansion of their single-use instrument product line into the U.S. The product leading the expansion is a gynecology product called the Cervical Rotating Biopsy Punch which supports urgently needed procedures like cancer diagnosis.

The single-use instrument was first introduced by DTR Medical Ltd (“DTR Medical”) in Wales in 2012 is now offered by Summit Medical LLC. (“Summit Medical”), a Minnesota based manufacturer of medical devices.

Since the initial development of the Cervical Rotating Biopsy Punch, the product has been used by numerous National Health Service (NHS) clinics and hospitals in the U.K. that have provided annual product feedback allowing for continuous product innovations. As part of an ongoing project with a leading Welsh University, a pioneering technique, known as biorefining, was used to recreate low carbon technologies for both the Cervical Rotating Biopsy Punch and it’s packaging. The instrument handle is now made of 20% renewably sourced propanediol (PDO) made from corn starch, making it both lightweight and recyclable. The polybag packaging was biorefined in 2020 to save 1,200 pounds of plastic each year. The Cervical Rotating Biopsy Punch has 2.8 times less of an environmental impact than other single-use products on the market like the metal Tischler Cervical Biopsy Punch and Baby Tischler Cervical Biopsy Punch.

Single-use instruments like the Cervical Rotating Biopsy Punch eliminate cross contamination, inadequate samples and repeat procedures. With Cervical cancer screenings down 68% in the U.S. due to COVID-19 [1], the importance of an adequate biopsy is essential in reducing the time to an accurate diagnosis.

“We believe introducing the Cervical Rotating Biopsy Punch to the U.S. is a natural expansion of our Single-Use Instrument category. Immediate benefits will improve the quality of patient care from acute care facilities to small offices that lack reprocessing environments. The quality of biopsy is notable and user feedback over the past decade has been extremely positive.” Said Marcus Super, Vice President of Marketing at Innovia Medical.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.